Intellia Therapeutics Inc is trading 10.2% up at $13.35 after releasing additional positive Phase 3 HAELO trial results for its hereditary angioedema gene-editing therapy, lonvoguran ziclumeran (lonvo‑z).
- The data demonstrated statistically significant reductions in HAE attacks and a favorable safety profile, reinforcing the potential for lonvo-z as a one-time treatment.
- The results have boosted investor sentiment toward the company’s CRISPR pipeline, coinciding with a broader risk-on move in the equity markets.